Understanding Nootropics for Mood & Stress
Mood and stress management have become central concerns in modern health. Chronic stress impairs cognitive function, emotional regulation, and overall quality of life, while mood disorders affect millions globally. While pharmaceutical interventions remain the gold standard for clinical depression and anxiety disorders, evidence-based nootropics offer a complementary approach for those seeking natural cognitive and mood support.
The challenge is distinguishing between marketing claims and genuine scientific evidence. This comprehensive guide ranks the best nootropics for mood and stress based on the quality and quantity of human research, effect sizes, consistency of findings, and safety profiles.
Ranking System: Understanding the Evidence Tiers
All nootropics covered in this article fall within Tier 3: Probable Efficacy. This means each demonstrates positive effects in human studies, but evidence is limited by factors such as small sample sizes, short study durations, lack of independent replication, or mixed results across trials. Tier 3 substances show promise but require larger, well-designed trials to confirm clinical significance.
The Best Nootropics for Mood & Stress
1. Ginkgo Biloba
What It Is Ginkgo biloba is an extract derived from the leaves of one of the world's oldest tree species. It contains unique compounds called ginkgoflavone glycosides and terpene lactones that cross the blood-brain barrier and modulate neurotransmitter systems.
Evidence Tier: Tier 3 — Probable Efficacy
Key Research Findings Ginkgo biloba demonstrates the most robust evidence profile among the nootropics reviewed here. A Bayesian network meta-analysis of 29 anxiety trials found that Ginkgo reduced Hamilton Anxiety Rating Scale (HAMA) scores by 4.63 points versus placebo (95% CrI: -9.01 to -0.23), suggesting clinically meaningful anxiety reduction.
More impressively, a double-blind RCT with 107 participants found that Ginkgo biloba EGb 761 at 480 mg daily reduced HAMA scores by 14.3 ± 8.1 points compared to 7.8 ± 9.2 for placebo (p=0.0003). A lower dose of 240 mg also proved effective (p=0.01), with a clear dose-response trend (p=0.003).
Dosing: 120–240 mg twice daily
Cost: $10–$35 per month
Best For: Individuals with generalized anxiety, age-related cognitive decline, or those seeking a well-researched botanical with mood benefits
2. Bacopa Monnieri
What It Is Bacopa monnieri, also called Brahmi, is a traditional Ayurvedic herb containing bacosides—alkaloid compounds that enhance neurotransmitter function and reduce neuroinflammation.
Evidence Tier: Tier 3 — Probable Efficacy
Key Research Findings Bacopa monnieri is supported by six human RCTs specifically examining mood and stress outcomes. In elderly adults (n=48, 12 weeks), Bacopa at 300 mg daily reduced anxiety on the State-Trait Anxiety Inventory and depression on the CESD-10 scale compared to placebo, with concurrent improvements in delayed recall and attention.
In anhedonia patients (n=42, 4 weeks), Bacopa at 300 mg twice daily combined with the SSRI citalopram produced significant improvements on the Hamilton Depression Rating Scale (p<.05) and the Snaith-Hamilton Pleasure Scale (SHAPS) versus citalopram alone. This suggests Bacopa may enhance antidepressant response.
Dosing: 300–600 mg once daily
Cost: $10–$35 per month
Best For: Those with comorbid anxiety and depression, age-related mood decline, or individuals taking antidepressants seeking augmentation
3. Phosphatidylserine
What It Is Phosphatidylserine is a phospholipid naturally present in cell membranes, particularly abundant in brain tissue. It modulates the hypothalamic-pituitary-adrenal (HPA) axis, the body's primary stress response system.
Evidence Tier: Tier 3 — Probable Efficacy
Key Research Findings Though limited to two small RCTs, phosphatidylserine shows promise for stress resilience. In one study (n=16, 42 days), chronic PS supplementation significantly decreased Beta-1 power in right frontal brain regions (F8; P<0.05) after induced stress, a neurophysiological marker associated with a more relaxed mental state compared to controls.
In another trial (n=190, 12 months), phosphatidylserine combined with alpha-lipoic acid and Ginkgo improved arithmetic testing performance (β=0.688; 95% CI 0.103–1.274) and similarity test scores in older adults with mild cognitive impairment, suggesting benefits extend to cognition under stress.
Dosing: 100–300 mg three times daily
Cost: $15–$50 per month
Best For: Those experiencing chronic stress, individuals with high cortisol, or older adults with cognitive concerns
4. Lion's Mane
What It Is Lion's Mane (Hericium erinaceus) is an edible mushroom containing bioactive compounds like hericenones and erinacines that stimulate nerve growth factor (NGF) production—a critical protein for brain health.
Evidence Tier: Tier 3 — Probable Efficacy
Key Research Findings Lion's Mane demonstrates modest but measurable benefits. In a study of 41 healthy adults, Lion's Mane supplementation increased Stroop task processing speed (p=0.005) 60 minutes post-dose, indicating improved cognitive control under stress.
The same study showed a trend toward reduced subjective stress after 28 days of supplementation (p=0.051), approaching statistical significance. While not conclusive, this suggests potential mood benefits with continued use.
Dosing: 500–1000 mg twice daily
Cost: $15–$60 per month
Best For: Individuals seeking cognitive support alongside mood benefits, those interested in neuroprotection, or those prioritizing natural whole-food sources
5. Bromantane
What It Is Bromantane (also marketed as Ladasten) is a Soviet-era synthetic adaptogen that enhances dopamine and serotonin function while reducing stress-induced impairments in cognition and mood.
Evidence Tier: Tier 3 — Probable Efficacy
Key Research Findings Bromantane demonstrates strong clinical response rates in multicenter trials. A large RCT (n=728) found a 76.0% responder rate on the Clinical Global Impression-Severity scale and 90.8% improvement on the Clinical Global Impression-Improvement scale with Bromantane 50–100 mg daily over 28 days. Notably, antiasthenic effects (reduced fatigue and apathy) were visible by day 3 and sustained one month post-withdrawal.
A placebo-controlled trial found Bromantane superior to placebo in reducing asthenic syndrome symptoms without withdrawal syndrome upon discontinuation—a significant safety advantage over some psychotropics.
Dosing: 50–100 mg once daily
Cost: $20–$55 per month
Best For: Individuals with mood apathy, fatigue-predominant depression, or those seeking mood support without sedation
6. Sulbutiamine
What It Is Sulbutiamine is a synthetic derivative of thiamine (vitamin B1) that crosses the blood-brain barrier more efficiently than B1 alone, enhancing thiamine-dependent energy metabolism in neural tissue.
Evidence Tier: Tier 3 — Probable Efficacy
Key Research Findings Sulbutiamine shows benefits for psychomotor retardation—the slowed thinking and motivation characteristic of depression. In a multicenter RCT, Sulbutiamine at 600 mg daily combined with clomipramine improved psycho-behavioral inhibition in major depression, with improvements on the Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, and Clinical Global Impression scores at 4 weeks.
However, results on fatigue are mixed. A study of 326 patients with chronic fatigue post-infection found reduced fatigue in women at day 7 (p<0.01), but this effect did not persist at 28 days.
Dosing: 400–600 mg once daily
Cost: $15–$45 per month
Best For: Those with depression-related fatigue and psychomotor slowing, particularly when combined with conventional antidepressants
7. Alpha-GPC
What It Is Alpha-GPC (L-alpha-glycerylphosphorylcholine) is a choline compound that increases acetylcholine and dopamine synthesis, neurotransmitters critical for motivation and mood regulation.
Evidence Tier: Tier 3 — Probable Efficacy
Key Research Findings Alpha-GPC's primary evidence comes from a single small RCT (n=39, 2 weeks). Motivation at night was significantly higher in the Alpha-GPC group versus placebo (p<0.05), with a tendency toward increased overall motivation during intervention (p<0.05). This suggests benefits primarily for motivational symptoms of depression.
While mechanistic studies support potential benefits for depression and stress-related conditions, the limited human evidence represents the main constraint on confidence.
Dosing: 300–600 mg once to twice daily
Cost: $15–$45 per month
Best For: Those with low motivation, apathy, or depressive symptoms characterized by lack of drive
8. Phenylpiracetam
What It Is Phenylpiracetam is a pyrrolidone derivative with added phenyl moiety that enhances dopamine and norepinephrine signaling while reducing stress-induced impairments in cognition and mood.
Evidence Tier: Tier 3 — Probable Efficacy
Key Research Findings Limited human evidence supports phenylpiracetam for mood. In one RCT with 35 cardiovascular patients, phenylpiracetam showed statistically significant anxiolytic and antidepressant improvements over 12 weeks, though the anxiolytic effect decreased after 4–8 weeks.
An observational study (n=99) found that phenylpiracetam at 200 mg daily for one month produced lower anxiety and depression with improved higher brain functions in patients with encephalopathy from brain lesions.
Animal studies consistently support anxiolytic and antidepressant properties, but human proof remains modest.
Dosing: 100–200 mg one to two times daily (maximum 2 doses per day)
Cost: $20–$60 per month
Best For: Those seeking cognitive enhancement with mood benefits, individuals with stress-related cognitive impairment
9. NSI-189
What It Is NSI-189 is a novel synthetic compound designed to enhance neuroplasticity and neurogenesis—the creation of new neurons in the hippocampus, a brain region critical for mood and memory.
Evidence Tier: Tier 3 — Probable Efficacy
Key Research Findings NSI-189's efficacy profile is the weakest among the nootropics reviewed. Two Phase 2 RCTs failed to meet primary endpoints. In one trial (n=220), NSI-189 at 40 mg and 80 mg produced mean reductions on the Montgomery-Åsberg Depression Rating Scale of only -1.8 and -1.4 points versus placebo (p=0.22 and p=0.34 respectively).
However, secondary endpoints showed promise: NSI-189 at 40 mg reduced the Symptoms of Depression Questionnaire by 8.2 points versus placebo (p=0.04) with a larger effect in Stage 2 analysis (Cohen's d = -0.64). This suggests efficacy may be limited to specific subgroups with moderate depression severity.
Dosing: 40 mg once daily
Cost: $30–$80 per month
Best For: Those with treatment-resistant depression, individuals specifically interested in neuroplasticity enhancement, though evidence remains preliminary
10. Caffeine
What It Is Caffeine is a methylxanthine alkaloid that antagonizes adenosine receptors, increasing dopamine and norepinephrine signaling—mechanisms underlying improved mood and attention.
Evidence Tier: Tier 3 — Probable Efficacy
Key Research Findings Caffeine improves mood and attention in many individuals, though effects are highly variable. A meta-analysis of 15 RCTs found that theanine plus caffeine improved digit vigilance accuracy (SMD 0.20, 95% CI 0.02–0.38) and attention switching accuracy (SMD 0.33, 95% CI 0.13–0.54) at 2 hours versus placebo in healthy adults.
Critically, individual responses vary dramatically by caffeine sensitivity and habitual consumption. In low habitual caffeine consumers (≤100 mg daily), 400 mg caffeine actually increased state anxiety, negative emotion, and salivary cortisol 45–75 minutes post-dose versus placebo (n=44, RCT).
Dosing: 100–200 mg one to two times daily
Cost: $3–$15 per month
Best For: Those with low habitual caffeine intake seeking mood and cognitive benefits; notably less suitable for anxiety-prone individuals or those with high baseline caffeine consumption